All Publications
-
Targeting cytokine-like protein FAM3D alleviates atherosclerosis.
Cell reports. Medicine
2026; 7 (7): 102908
Abstract
Despite effective cholesterol-lowering medications, significant residual cardiovascular risk related to atherosclerosis remains. Here, we explore whether the cytokine-like protein FAM3D contributes to atherosclerosis. Clinical cohort data reveal that elevated circulating FAM3D levels are strongly associated with human atherosclerosis. Both global and intestinal epithelial cell-specific Fam3d deficiencies significantly inhibit intestinal cholesterol and triglyceride absorption and mitigate atherosclerosis in mice. Mechanistically, FAM3D upregulates microsomal triglyceride transfer protein (MTTP) expression and activity, promoting chylomicron assembly in intestinal epithelial cells. Meanwhile, endothelial FAM3D induces vascular smooth muscle cell (VSMC) dedifferentiation via a lipid-independent mechanism. Both effects are mediated by the formyl peptide receptor 1 (FPR1)-Gαi/Gαq signaling cascade. Importantly, two monoclonal antibodies targeting FAM3D effectively suppress intestinal MTTP-mediated chylomicron assembly and VSMC dedifferentiation, thereby mitigating atherosclerosis in mice. In conclusion, FAM3D exacerbates atherosclerosis through both lipid-dependent and lipid-independent mechanisms, representing a promising therapeutic target for combating residual cardiovascular risk unresolved by current cholesterol-lowering therapies.
View details for DOI 10.1016/j.xcrm.2026.102908
View details for PubMedID 42385709
View details for PubMedCentralID PMC13400176
-
Adipose-Derived FAM19A5 Inhibits Both Vascular Calcification and Osteoporosis in Mice.
Circulation research
2026; 139 (1): e327708
Abstract
Vascular calcification and osteoporosis often co-occur during postmenopause, end-stage renal disease, advancing age, and diabetes, leading to increased mortality and significant challenges in therapy. FAM19A5 (family with sequence similarity 19 [chemokine (C-C motif)-like], member A5), as a novel protective adipokine, has been identified to suppress postinjury neointima formation. However, the involvement of adipose-derived FAM19A5 in vascular calcification and osteoporosis remains unclear.A cross-sectional study was conducted to assess the relationship among circulating FAM19A5, coronary artery calcification, and osteoporosis. Adipose-specific FAM19A5 transgenic mice and AAV8 (adeno-associated virus serum type 8)-adipo-shFAM19A5 were employed to study gain or loss of function of FAM19A5 in 2 distinct mouse models: ovariectomy followed by Vitamin D3 overload (OVX-VitD3) and adenine diet. Calcium assays, micro-CT, Western blot, RT-qPCR, luciferase reporter assays, and ChIP-qPCR were performed to clarify the phenotype and elucidate the molecular mechanisms. Finally, administration of AAV8-adipoq-FAM19A5 and S1PR2 (sphingosine 1-phosphate receptor 2) global knockout mice was used to investigate their therapeutic effects.Circulating FAM19A5 was negatively correlated with coronary artery calcification and osteoporosis in patients and mouse models. Adipose-specific FAM19A5 transgenic mice exhibited milder aortic calcification and preserved bone mass via S1PR2 in both OVX-VitD3 and adenine diet models. Although adipose-specific knockdown of FAM19A5 aggravates aortic calcification and bone mass loss. Interestingly, FAM19A5 mitigated vascular smooth muscle cells' calcification by activating S1PR2-Gi-PKA signaling and promoted mice osteoblasts differentiation by triggering S1PR2-Gq-PKCδ (protein kinase C delta isoform) signaling. Finally, administration of AAV8-adipoq-FAM19A5 effectively rescued vascular calcification and osteoporosis, but exerted no beneficial effects in S1PR2 knockout mice.Adipose-derived FAM19A5 plays an essential role in orchestrating vascular calcification and osteoporosis through the selective activation of S1PR2. Our findings provide novel insight into the previously unexplored role of adipose tissue in maintaining vascular-bone homeostasis. FAM19A5-S1PR2 may be considered as a potential therapeutic strategy for vascular calcification and osteoporosis.
View details for DOI 10.1161/CIRCRESAHA.125.327708
View details for PubMedID 42089142
-
Calcium channel blockers increase the risk of aortic aneurysm and dissection.
Nature communications
2025; 17 (1): 1334
Abstract
Aortic aneurysm and dissection (AAD) are life-threatening conditions without effective medications. Impaired contractility of vascular smooth muscle cells (VSMCs) is strongly linked to AAD, but the role of calcium channel blockers (CCBs), which directly inhibits VSMC contractility, in AAD remains unclear. Here we showed data from 501,878 initially AAD-free participants in UK Biobank. Over a median follow-up of 13.5 years, CCB users had higher AAD risk (HR = 1.31) than hypertensive patients not receiving antihypertensive treatment. In mouse models of AAD, CCBs significantly aggravated aortic stiffness and AAD development. For patients with type B aortic dissection who underwent endovascular repair, CCBs limited AAD regression compared with other antihypertensives. Moreover, silencing of protein kinase cGMP-dependent 1 (PRKG1) significantly mitigated CCB-aggravated AAD progression. These findings suggest that CCBs may increase AAD risk and post-stent surgery prognosis, highlighting the need for caution when prescribing CCBs to hypertensive patients at risk for AAD.
View details for DOI 10.1038/s41467-025-68086-5
View details for PubMedID 41444229
View details for PubMedCentralID PMC12873303
-
Sensing ceramides by CYSLTR2 and P2RY6 to aggravate atherosclerosis.
Nature
2025; 641 (8062): 476-485
Abstract
Recent evidence has shown that increased levels of circulating long-chain ceramides predict atherosclerotic cardiovascular disease independently of cholesterol1,2. Although targeting ceramide signalling may provide therapeutic benefits beyond the treatment of hypercholesterolaemia, the underlying mechanism by which circulating ceramides aggravate atherosclerotic cardiovascular disease remains elusive. Here we examine whether circulating long-chain ceramides activate membrane G-protein-coupled receptors to exacerbate atherosclerosis. We perform a systematic screen that combines G-protein-signalling quantification, bioinformatic analysis of G-protein-coupled receptor expression and functional examination of NLRP3 inflammasome activation. The results suggest that CYSLTR2 and P2RY6 are potential endogenous receptors of C16:0 ceramide-induced inflammasome activation in both endothelial cells and macrophages. Inhibition of CYSLTR2 and P2RY6 genetically or pharmacologically alleviates ceramide-induced atherosclerosis aggravation. Moreover, increased ceramide levels correlate with the severity of coronary artery disease in patients with varying degrees of renal impairment. Notably, CYSLTR2 and P2RY6 deficiency mitigates chronic-kidney-disease-aggravated atherosclerosis in mice without affecting cholesterol or ceramide levels. Structural analyses of ceramide-CYSLTR2-Gq complexes reveal that both C16:0 and C20:0 ceramides bind in an inclined channel-like ligand-binding pocket on CYSLTR2. We further reveal an unconventional mechanism underlying ceramide-induced CYSLTR2 activation and the CYSLTR2-Gq interface. Overall, our study provides structural and molecular mechanisms of how long-chain ceramides initiate transmembrane Gq and inflammasome signalling through direct binding to CYSLTR2 and P2RY6 receptors. Therefore, blocking these signals may provide a new therapeutic potential to treat atherosclerosis-related diseases.
View details for DOI 10.1038/s41586-025-08792-8
View details for PubMedID 40049228
-
Activin Receptor-Like Kinase 3 Directly Couples Gαq (Guanine Nucleotide-Binding Protein Subunit αq)/ Gαq (Guanine Nucleotide-Binding Protein Subunit α11) to Regulate Vascular Contractility.
Hypertension (Dallas, Tex. : 1979)
2023; 80 (6): 1231-1244
Abstract
Vascular smooth muscle cell (VSMC) contractility is critical for blood pressure regulation and vascular homeostasis. Identifying the key molecule that maintains VSMC contractility may provide a novel therapeutic target for vascular remodeling. ALK3 (activin receptor-like kinase 3) is a serine/threonine kinase receptor, and deletion of ALK3 causes embryonic lethality. However, little is known about the role of ALK3 in postnatal arterial function and homeostasis.We conducted in vivo studies in a tamoxifen-induced postnatal VSMC-specific ALK3 deletion mice suitable for analysis of blood pressure and vascular contractility. Additionally, the role of ALK3 on VSMC was determined using Western blot, collagen-based contraction assay and traction force microscopy. Furthermore, interactome analysis were performed to identify the ALK3-associated proteins and bioluminescence resonance energy transfer assay was used to characterize Gαq activation.ALK3 deficiency in VSMC led to spontaneous hypotension and impaired response to angiotensin II in mice. In vivo and in vitro data revealed that ALK3 deficiency impaired contraction force generation by VSMCs, repressed the expression of contractile proteins, and inhibited the phosphorylation of myosin light chain. Mechanistically, Smad1/5/8 signaling mediated the ALK3-modulated contractile protein expressions but not myosin light chain phosphorylation. Furthermore, interactome analysis revealed that ALK3 directly interacted with and activated Gαq (guanine nucleotide-binding protein subunit αq)/Gα11 (guanine nucleotide-binding protein subunit α11), thereby stimulating myosin light chain phosphorylation and VSMC contraction.Our study revealed that in addition to canonical Smad1/5/8 signaling, ALK3 modulates VSMC contractility through direct interaction with Gαq/Gα11, and therefore, might serve as a potential target for modulating aortic wall homeostasis.
View details for DOI 10.1161/HYPERTENSIONAHA.122.20654
View details for PubMedID 36999441
-
A Calcium Phosphate-Induced Mouse Abdominal Aortic Aneurysm Model.
Journal of visualized experiments : JoVE
2022
Abstract
An abdominal aortic aneurysm (AAA) is a life-threatening cardiovascular disease that occurs worldwide and is characterized by irreversible dilation of the abdominal aorta. Currently, several chemically induced murine AAA models are used, each simulating a different aspect of the pathogenesis of AAA. The calcium phosphate-induced AAA model is a rapid and cost-effective model compared to the angiotensin II- and elastase-induced AAA models. The application of CaPO4 crystals to the mouse aorta results in elastic fiber degradation, loss of smooth muscle cells, inflammation, and calcium deposition associated with aortic dilation. This article introduces a standard protocol for the CaPO4-induced AAA model. The protocol includes material preparation, the surgical application of the CaPO4 to the adventitia of the infrarenal abdominal aorta, the harvesting of aortas to visualize aortic aneurysms, and histological analyses in mice.
View details for DOI 10.3791/64173
View details for PubMedID 36468709
-
PHB2 Maintains the Contractile Phenotype of VSMCs by Counteracting PKM2 Splicing.
Circulation research
2022; 131 (10): 807-824
Abstract
Phenotypic transition of vascular smooth muscle cells (VSMCs) accounts for the pathogenesis of a variety of vascular diseases during the early stage. Recent studies indicate the metabolic reprogramming may be involved in VSMC phenotypic transition. However, the definite molecules that link energy metabolism to distinct VSMC phenotype remain elusive.A carotid artery injury model was used to study postinjury neointima formation as well as VSMC phenotypic transition in vivo. RNA-seq analysis, cell migration assay, collagen gel contraction assay, wire myography assay, immunoblotting, protein interactome analysis, co-immunoprecipitation, and mammalian 2-hybrid assay were performed to clarify the phenotype and elucidate the molecular mechanisms.We collected cell energy-regulating genes by using Gene Ontology annotation and applied RNA-Seq analysis of transforming growth factor-β or platelet-derived growth factor BB stimulated VSMCs. Six candidate genes were overlapped from energy metabolism-related genes and genes reciprocally upregulated by transforming growth factor-β and downregulated by platelet-derived growth factor BB. Among them, prohibitin 2 has been reported to regulate mitochondrial oxidative phosphorylation. Indeed, prohibitin 2-deficient VSMCs lost the contractile phenotype as evidenced by reduced contractile proteins. Consistently, Phb2SMCKO mice were more susceptible to postinjury VSMC proliferation and neointima formation compared with Phb2flox/flox mice. Further protein interactome analysis, co-immunoprecipitation, and mammalian 2-hybrid assay revealed that prohibitin 2, through its C-terminus, directly interacts with hnRNPA1, a key modulator of pyruvate kinase M1/2 (PKM) mRNA splicing that promotes PKM2 expression and glycolysis. Prohibitin 2 deficiency facilitated PKM1/2 mRNA splicing and reversion from PKM1 to PKM2, and enhanced glycolysis in VSMCs. Blocking prohibitin 2-hnRNPA1 interaction resulted in increased PKM2 expression, enhanced glycolysis, repressed contractile marker genes expression in VSMCs, as well as aggravated postinjury neointima formation in vivo.Prohibitin 2 maintains VSMC contractile phenotype by interacting with hnRNPA1 to counteract hnRNPA1-mediated PKM alternative splicing and glucose metabolic reprogramming.
View details for DOI 10.1161/CIRCRESAHA.122.321005
View details for PubMedID 36200440
https://orcid.org/0009-0000-2800-6525